SCHEMBL21149

SCHEMBL21149

Cc1cc(C)cc(Nc2nc3c(-c4cccc(C(N)=O)c4)nccn3n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 12/20 0.46
MAP2K4 P45985 1/20 0.41
DHODH Q02127 1/20 0.41
PIK3CG P48736 1/20 0.40
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
YES1 P07947 1/20 0.39
LYN P07948 1/20 0.39
FGR P09769 1/20 0.39
EPHA1 P21709 1/20 0.39
EPHA2 P29317 1/20 0.39
EPHA3 P29320 1/20 0.39
EPHB2 P29323 1/20 0.39
CSK P41240 1/20 0.39
TXK P42681 1/20 0.39
BLK P51451 1/20 0.39
BMX P51813 1/20 0.39
EPHB3 P54753 1/20 0.39
EPHA5 P54756 1/20 0.39
EPHA4 P54764 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535 0.88 SYK (0.48) SYKPIK3CGFLT1FLT4KDR
SCHEMBL21230 0.85 KDR (0.43) SYKFLT1FLT4KDR
SCHEMBL15207265 0.84 MAP4K4 (0.42) SYKLYNFLT1FLT4KDR
SCHEMBL20406 0.83 FYN (0.49) SYKPIK3CGFYN
SCHEMBL20549 0.83 SYK (0.49) SYKFYN
SCHEMBL20010 0.83 KDR (0.52) SYKFLT1FLT4KDR
SCHEMBL15207171 0.82 KDR (0.41) SYKFLT1FLT4KDR
SCHEMBL15208070 0.82 SYK (0.50) SYKFYN
SCHEMBL20147 0.81 JAK2 (0.55) BTK
SCHEMBL20253 0.80 KDR (0.54) SYKFLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609098-A1 TRIAZOLOPYRAZINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025186-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 SYK 1/4885MAP2K4 994/4885DHODH 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.